Podcast

Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters

Author(s):

Urology Times staff

“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.

In this episode, Urology Times® Managing Editor Ben Saylor spoke with Amy E. Krambeck, MD. She discusses the recent Journal of Endourology study, "Multi-institutional prospective randomized control trial of novel intracorporeal lithotripters: ShockPulse-SE vs Trilogy trial," for which she served as senior author. Krambeck is a professor of urology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Related Videos
Human kidney stones | Image Credit: © freshidea - stock.adobe.com
Thomas Chi, MD, MBA, answers a question during a Zoom video interview
Human kidney stones | Image Credit: © freshidea - stock.adobe.com
Thomas Chi, MD, MBA, answers a question during a Zoom video interview
Victoria S. Edmonds, MD, answers a question during a Zoom video interview
Human kidney stones | Image Credit: © freshidea - stock.adobe.com
DNA strand illustration | Image Credit: © Radomir Jovanovic - stock.adobe.com
Magnifying glass examining DNA | Image Credit: © Giovanni Cancemi - stock.adobe.com
Related Content
FDA grants de novo clearance to Stone Clear device
November 13th 2024

FDA grants de novo clearance to Stone Clear device

Hannah Clarke
"The Stone Clear device provides patients with a non-invasive option to reduce their residual fragment stone burden in the clinic environment while being fully awake," says James E. Lingeman, MD.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
Ultrasonic propulsion for clearance of residual kidney stone fragments reduces relapse
August 29th 2024

Ultrasonic propulsion for clearance of residual kidney stone fragments reduces relapse

Hannah Clarke
In total, 8 of 40 patients who underwent ultrasonic propulsion experienced relapse, compared with 21 of 42 patients who underwent observation.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
Trial launches of gene editing therapy for primary hyperoxaluria type 1
August 24th 2024

Trial launches of gene editing therapy for primary hyperoxaluria type 1

Hannah Clarke
In total, the trial plans to enroll 7 patients with PH1 through a single center in China.
Data suggest Break Wave lithotripsy is safe, effective for urolithiasis
August 21st 2024

Data suggest Break Wave lithotripsy is safe, effective for urolithiasis

Hannah Clarke
Any stone fragmentation was achieved in 88% of patients.
© 2024 MJH Life Sciences

All rights reserved.